menu

CME: Systemic Sclerosis Interstitial Lung Disease: A Multidisciplinary Approach to Diagnosis & Longitudinal Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Systemic Sclerosis Interstitial Lung Disease: A Multidisciplinary Approach to Diagnosis, Treatment, & Longitudinal Management

close
1.00 credits
60 minutes
Systemic Sclerosis Interstitial Lung Disease: A Multidisciplinary Approach to Diagnosis, Treatment, & Longitudinal Management
RestartResume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Systemic sclerosis (SSc) is a rare disease characterized most often by skin thickening and referred to as scleroderma. This chronic disease involves internal organs and often leads to intestinal, kidney, lung, and heart problems. Interstitial Lung Disease (ILD) is one of the leading causes of death for patients with systemic sclerosis. Therefore, early diagnosis and treatment of SSc-ILD is critical to positively impact the prognosis for patients. However, arriving at a diagnosis of SSc-ILD can be very challenging for many physicians because of the inherent complexity of SSc and gaps in knowledge about this relatively rare condition. This program will assist healthcare providers to better identify risk factors, clinical features and co-morbidities associated with SSc-ILD and provide an overview of the evidence related to current and emerging therapies for the treatment of SSc-ILD. This program will also highlight considerations for the longitudinal management of SSc-ILD using a multidisciplinary approach.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME/CE approval committee, and those in a position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties. All CME/CE educational activities sponsored by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

    Faculty Presenters
    Mehrnaz Maleki Fischbach, MD has no financial relationships to disclose.
    Maria Padilla, MD discloses that she is on an advisory board for Boehringer Ingelheim, a consultant for Genentech and Takeda as well as a speaker for Genentech and American College of Allergy and Immunology.
    Jesse Roman, MD discloses that he is on a steering committee for Boehringer Ingelheim and conducts research for Galapagos, Genentech and Galecto Biotech.
    Jeffrey Swigris, DO, MS discloses that he is a consultant and receives grant funding for Boehringer Ingelheim and Genenetch as well as a speaker for Genentech.

    Program Planners and Reviewers
    Mandy Comeau has no relevant financial relationships to disclose.
    Stephanie Corder, ND, RN has no relevant financial relationships to disclose.
    Lia R. Matarrese McGibbon, DO has no releveant financial relationships to disclose.
    Amen Sergew, MD has no relevant financial relationships to disclose.

  • Target Audience

    This activity is intended for pulmonologists, rheumatologists and any others who treat patients with SSc-ILD.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    1. Identify clinical features and risk factors of SSc-ILD based upon best practices for diagnosis.
    2. Apply practice guidelines and clinical evidence related to current and emerging therapies to select treatments for patients with SSc-ILD.
    3. Evaluate strategies for longitudinal management of SSc-ILD using a multidisciplinary approach.
  • Accreditation and Credit Designation Statements

    Accreditation and Designation Statements:
    Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This collaborative program was developed and presented by National Jewish Health with the Mount Sinai – National Jewish Health Respiratory Institute and the Jane and Leonard Korman Respiratory Institute -  Jefferson Health and National Jewish Health. Together, these three organizations collaborate on research, clinical trials and other programs extending the impact they bring to patients and furthering the understanding of respiratory illness.The Respiratory Institute model of collaboration currently brings these three entities together, collectively referred to as “The Respiratory Institutes”.

    The Respiratory Institutes provide specialized programs committed to multidisciplinary consultation, advanced diagnostics, and coordinated, collaborative care for the full range of lung conditions. With expert faculty working in sync, the Institutes are well-positioned to provide education to health care providers on best practices in respiratory medicine and improving overall care coordination. 

     

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Systemic sclerosis (SSc) is a rare disease characterized most often by skin thickening and referred to as scleroderma. This chronic disease involves internal organs and often leads to intestinal, kidney, lung, and heart problems. Interstitial Lung Disease (ILD) is one of the leading causes of death for patients with systemic sclerosis. Therefore, early diagnosis and treatment of SSc-ILD is critical to positively impact the prognosis for patients. However, arriving at a diagnosis of SSc-ILD can be very challenging for many physicians because of the inherent complexity of SSc and gaps in knowledge about this relatively rare condition. This program will assist healthcare providers to better identify risk factors, clinical features and co-morbidities associated with SSc-ILD and provide an overview of the evidence related to current and emerging therapies for the treatment of SSc-ILD. This program will also highlight considerations for the longitudinal management of SSc-ILD using a multidisciplinary approach.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME/CE approval committee, and those in a position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties. All CME/CE educational activities sponsored by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

    Faculty Presenters
    Mehrnaz Maleki Fischbach, MD has no financial relationships to disclose.
    Maria Padilla, MD discloses that she is on an advisory board for Boehringer Ingelheim, a consultant for Genentech and Takeda as well as a speaker for Genentech and American College of Allergy and Immunology.
    Jesse Roman, MD discloses that he is on a steering committee for Boehringer Ingelheim and conducts research for Galapagos, Genentech and Galecto Biotech.
    Jeffrey Swigris, DO, MS discloses that he is a consultant and receives grant funding for Boehringer Ingelheim and Genenetch as well as a speaker for Genentech.

    Program Planners and Reviewers
    Mandy Comeau has no relevant financial relationships to disclose.
    Stephanie Corder, ND, RN has no relevant financial relationships to disclose.
    Lia R. Matarrese McGibbon, DO has no releveant financial relationships to disclose.
    Amen Sergew, MD has no relevant financial relationships to disclose.

  • Target Audience

    This activity is intended for pulmonologists, rheumatologists and any others who treat patients with SSc-ILD.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    1. Identify clinical features and risk factors of SSc-ILD based upon best practices for diagnosis.
    2. Apply practice guidelines and clinical evidence related to current and emerging therapies to select treatments for patients with SSc-ILD.
    3. Evaluate strategies for longitudinal management of SSc-ILD using a multidisciplinary approach.
  • Accreditation and Credit Designation Statements

    Accreditation and Designation Statements:
    Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This collaborative program was developed and presented by National Jewish Health with the Mount Sinai – National Jewish Health Respiratory Institute and the Jane and Leonard Korman Respiratory Institute -  Jefferson Health and National Jewish Health. Together, these three organizations collaborate on research, clinical trials and other programs extending the impact they bring to patients and furthering the understanding of respiratory illness.The Respiratory Institute model of collaboration currently brings these three entities together, collectively referred to as “The Respiratory Institutes”.

    The Respiratory Institutes provide specialized programs committed to multidisciplinary consultation, advanced diagnostics, and coordinated, collaborative care for the full range of lung conditions. With expert faculty working in sync, the Institutes are well-positioned to provide education to health care providers on best practices in respiratory medicine and improving overall care coordination. 

     

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/24/20